Articles tagged with Type 1 Diabetes
A study at the University of Gothenburg found that intensive treatment with remote monitoring of glucose levels and weekly healthcare contact significantly improved long-term blood glucose control in people with type 1 diabetes. The treatment also increased patient satisfaction and proved to be safe, with no serious events reported.
A new study published in JAMA demonstrates that an AI-powered lifestyle intervention app for prediabetes can reduce the risk of diabetes similarly to traditional, human-led programs. The app achieved higher rates of program initiation and completion compared to traditional programs.
A low-fat vegan diet has been shown to improve insulin sensitivity and reduce the amount of insulin needed in people with type 1 diabetes. This can lead to significant cost savings, with total insulin costs decreasing by 27% in a recent study.
A study found a significant increase in type 1 diabetes cases among children under five and young adult men in Sweden during the Covid-19 pandemic. The incidence of diabetes increased by 12% in 2021 and 9% in 2022 compared to previous years, with no clear connection between Covid-19 infection and diabetes.
A new lab-designed protein has been discovered to regulate blood glucose levels, offering a potential new treatment avenue for people with Type 1 diabetes. The substance combines insulin and glucagon into one molecule, signaling the liver to respond naturally.
Poor blood sugar control in adolescence increases the risk of painful future complications for people with type 1 diabetes. Children diagnosed with type 1 diabetes at a young age have trouble controlling their blood sugar as teens and are more likely to develop neuropathy in adulthood.
A new trial has shown that a lower dose of the immunomodulatory drug ATG is safe and effective in preventing the progression of type 1 diabetes in young people. The study found that the drug was able to arrest or delay the progression of T1D at a dose as low as 0.5mg/kg, with a good safety profile.
The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, with the greatest increases expected in Africa and the Middle East/North Africa. The analysis reveals substantial global inequities in diabetes care and outcomes.
The Ver-A-T1D trial suggests that verapamil could preserve beta-cell function in adults with newly diagnosed type 1 diabetes. The study demonstrated encouraging trends towards beta-cell preservation and well-established safety profile, but narrowly missed statistical significance.
A daily pill of baricitinib, a Janus kinase inhibitor, preserves insulin-producing beta cell function and slows type 1 diabetes progression in people recently diagnosed with the condition. The treatment's therapeutic effect is lost when it's stopped, justifying its testing in earlier stages to prevent or delay clinical diagnosis.
A four-year NIH grant will support a study of type 1 diabetes, led by Dr. Shuibing Chen at Weill Cornell Medicine. The researchers will investigate the interplay between genetic and environmental triggers using advanced laboratory and computational tools.
Lantidra, the only FDA-approved therapy for brittle type 1 diabetes, allows patients to stop taking daily insulin injections. The treatment has been shown to preserve health and prevent complications associated with diabetes.
The Pennington Biomedical Research Center has opened a new Endocrinology and Diabetes Clinic in Baton Rouge, providing specialized care for patients managing diabetes and endocrine disorders. The clinic is led by Dr. Timothy Gilbert, who brings nearly 20 years of private practice experience to the region.
A new study found that younger men with type 2 diabetes are more likely to experience worse cardiovascular disease and mortality outcomes compared to those with type 1 diabetes. In contrast, women with type 1 diabetes face poorer health outcomes across all ages, particularly due to longer exposure to high blood sugar levels and less ag...
A large-scale study published in PLOS Medicine found no association between early life antibiotic exposure and the development of autoimmune diseases in children. Researchers analyzed data from over 4 million Korean children and discovered no increased risk of Type 1 diabetes, Juvenile idiopathic arthritis, or other autoimmune conditions.
Researchers at UVA Health System are developing AI-based systems that can automatically detect meals and deliver insulin doses. The goal is to create fully automated artificial pancreas systems that require minimal user interaction.
Researchers uncover a critical endocrine link between brown adipocytes and pancreatic β-cells, revealing the ZNF638-RBP4-retinol-ATRA pathway's role in T1D pathogenesis. Targeting this axis may halt disease progression.
A study by Uppsala University found that parents of children with type 1 diabetes experience a significant drop in work-related incomes, particularly mothers. The impact is most pronounced for mothers of children diagnosed in preschool years. Long-term effects show that pension-qualifying incomes gradually decrease over time.
A new study found substantial increases in the use of continuous glucose monitoring and insulin delivery devices among children and adults with type 1 diabetes, resulting in improved blood-sugar control rates from 7% to 19% and 21% to 28%, respectively
A rapid increase in diabetes technology adoption led to improved glycemic control among type 1 diabetes patients, yet racial and socioeconomic disparities persisted. Notable racial and ethnic differences grew over time, highlighting the need for targeted interventions.
Researchers identified a sugar molecule called sialic acid that helps cancer cells evade the immune system. By engineering beta cells to produce this molecule, they found it possible to tolerate these cells and prevent their destruction. The study offers new hope for treating type 1 diabetes without immunosuppression.
A new study finds that living in rural areas in the first five years of life may be a risk factor for developing type 1 diabetes, whereas urban environments are associated with lower risk. The research identified significant high-risk clusters in rural areas and low-risk clusters in cities.
A new analysis published in The Journal of Clinical Investigation reveals how leptin affects the brain and its potential use in future therapeutics for type 1 diabetes. Leptin helps regulate appetite and body weight, and insufficient levels lead the brain to activate circuits that mobilize energy sources, including glucose and ketones.
A UNLV study uses an mRNA cocktail to selectively route to the pancreas, reducing the risk of immune responses and side effects. The breakthrough offers new hope for treating pancreas-related diseases, including cancer and diabetes.
A study assessing the Enhanced Primary Care Diabetes model found that Black patients were less likely to meet diabetes care goals, despite more frequent nurse touchpoints. Younger age, insulin use, and fewer initial medication counts were associated with slower progress.
A new web-based tool, Coverage Checker, helps Michigan physicians navigate diabetes coverage and prior authorization. The tool shows care team members which insurance policies cover guideline-directed medical therapy and continuous glucose monitors, and the prior authorization steps required.
Researchers have discovered a non-autoimmune form of type 1 diabetes prevalent in young people in Sub-Saharan Africa, differing from the typical autoimmune pattern seen in other regions. The study's findings also suggest an ancestral or genetic link between this subtype and African ancestry in the US.
A new subtype of diabetes has been identified in sub-Saharan Africa affecting nearly two-thirds of young people thought to have type 1 diabetes. This non-autoimmune form lacks typical features such as autoimmunity and genetic susceptibility, raising concerns about diagnosis and treatment.
A study found that automated insulin delivery pumps improved quality of life and reduced diabetes-related complications, with a cost-effectiveness ratio of 11,184 euros per quality-adjusted life-year. The technology is now supported for patients with type 1 diabetes in Finland.
A new study suggests that erythritol, commonly used in low-carb products, can alter the function of brain microvascular endothelial cells, leading to increased risk of stroke. The sugar substitute was found to constrict blood vessels and reduce the production of natural clot-busting compounds.
The Endocrine Society's new Scientific Statement identifies potential research directions to improve treatment options for people with type 1 diabetes. The statement highlights the need for population-based screening and more research into the causes of the disease.
Researchers identify new group of immune cells driving autoimmune attack on insulin-producing cells in pancreas during cancer immunotherapy. JAK inhibitors, already FDA-approved for psoriasis and arthritis, show potential to prevent and even reverse type 1 diabetes in preclinical models.
Replacing animal products with plant-based foods, including ultra-processed ones, leads to significant weight loss and improved insulin sensitivity in people with type 1 diabetes. A secondary analysis of a randomized clinical trial found that the vegan group experienced reduced body weight and increased insulin sensitivity.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
A team of international scientists successfully 3D printed functional human islets using a novel bioink, paving the way for more effective and less invasive treatment options. The bioprinted constructs maintained their structure without clumping or breaking down and showed promising results in laboratory tests.
A clinical trial found that semaglutide, a Type 2 diabetes drug, improved blood sugar levels and weight loss in adult Type 1 diabetes patients who use automated insulin delivery systems. The study showed that 36% of patients taking semaglutide achieved target blood glucose levels and lost at least 5% of their body weight.
Researchers discovered that a protein called BNIP3 plays a critical role in preserving mitochondrial health and reducing immune responses in type 1 diabetes. Boosting BNIP3 activity may help preserve beta cell function and prevent cellular destruction.
A new clinical trial found that taking semaglutide once weekly significantly improves blood sugar levels and leads to substantial weight loss in adults with Type 1 diabetes. The study involved 72 participants across four medical centers and showed a 36% improvement rate compared to the placebo group.
A landmark review highlights how diabetes alters bone microarchitecture and increases fracture risk in people with type 2 diabetes, despite normal or elevated bone mineral density. The authors advocate for updated diagnostic tools, including a revised TBS algorithm, to more accurately reflect bone quality in individuals with central ob...
Critical Path Institute's Translational Therapeutics Accelerator awards $250,000 to researchers advancing a promising therapeutic pathway for type 1 diabetes. The project aims to address key challenges in T1D treatment, including beta-cell preservation and immune system modulation.
A new study published in npj Digital Medicine found that an interactive artificial pancreas system, using digital twins, improved blood sugar control and reduced hemoglobin A1c levels in type 1 diabetes patients. The system adapts to users' changing bodies and allows them to test changes to the system's parameters in a safe simulation ...
A new study from the University of Colorado Anschutz Medical Campus shows that primary care clinics can effectively introduce continuous glucose monitors (CGMs) into their practices. The study found that both self-guided and virtual CGM initiation services were successful, regardless of clinic size or diabetes expertise.
Researchers have discovered a key marker, FXYD2, that identifies functional maturity and heterogeneity of stem cell-derived islet organoids. This breakthrough enables quality control for production of transplantable islets, advancing the field toward safer and more effective islet replacement therapies.
Researchers developed a new approach to identify healed diabetic foot ulcers at risk of reopening based on trans-epidermal water loss measurements. High TEWL values were linked to increased wound recurrence and shorter time to recurrence, suggesting functional skin barrier defects are a critical factor in wound healing.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
Scientists have created a vascularized organoid model of hormone-secreting cells in the pancreas, promising to improve diabetes research and cell-based therapies. The model, developed by Max Delbrück Center researchers, contains greater numbers of mature beta cells and secretes more insulin than non-vascularized counterparts.
A new study found that adults diagnosed with type 1 diabetes after age 40 have a higher risk of cardiovascular disease and death compared to those diagnosed earlier. Poor glucose control, obesity, and smoking are the main risk factors identified in the study.
A systematic review of 46 clinical studies with 4,113 participants found that automated insulin delivery (AID) systems improved time in target range and reduced elevated glucose values compared to conventional pump therapy. However, low efficacy was observed during periods with very low glucose levels.
A new approach targeting inflammation may help prevent or slow the progression of Type 1 diabetes by blocking TYK2 protein signaling. Researchers found that inhibiting this protein reduced harmful inflammation in the pancreas and protected insulin-producing beta cells.
Researchers at Carnegie Mellon University have developed a novel FRESH bioprinting technique that enables the creation of microphysiologic systems entirely out of collagen, cells, and other proteins. This advancement expands the capabilities of studying disease and building tissues for therapy, such as Type 1 diabetes.
Researchers Schmidt and Selvin will explore the connections between cardiovascular disease and diabetes, with a focus on large white blood cells and wearable continuous glucose monitors. Their work aims to develop new treatment therapies and improve health outcomes for people with diabetes.
A study published in Diabetes, Obesity and Metabolism found that obesity rates among type 1 diabetes patients increased for all age groups and ethnicities from 2008 to 2023. GLP-1 receptor agonist use also rose sharply, with a sevenfold increase in severely obese youth with type 1 diabetes between 2008-11 and 2020-23.
Research in mice suggests that antibiotics during infancy can stunt insulin-producing cell growth and boost diabetes risk. Specific microorganisms, such as Candida dubliniensis, may help promote pancreatic cell development and improve metabolic function.
The Dexcom G7 CGM device demonstrated an accuracy of 8.0% in a study involving 130 adults with type 1 or type 2 diabetes, setting a new standard for continuous glucose monitoring devices.
The INHALE-3 extension study found that a regimen of inhaled technosphere insulin and insulin degludec reduced post-meal hyperglycemia in adults with type 1 diabetes. The treatment showed significant improvements in mean time in range, with 43% of participants expressing interest in continuing the regimen.
A new study from the University of Surrey found that healthcare professionals face difficulties in recognizing and addressing disordered eating in people with type 1 Diabetes due to lack of support and limited confidence. This can lead to delays in diagnosis and potentially life-threatening complications for patients.
A phase 1/2 clinical trial is exploring whether denosumab, an osteoporosis medication, can protect and regenerate beta cells in people with early type 1 diabetes. The study aims to improve blood sugar control by preserving beta cell function.
Researchers emphasize the importance of regular screenings and treatment to prevent vision loss in patients with diabetes. Current guidelines recommend eye exams for adults with type 1 and type 2 diabetes, while adolescents and young adults are at higher risk due to difficulty controlling their condition.
A new study from Washington State University finds automated insulin delivery systems safe and effective for older adults with type 1 diabetes, improving glucose control and reducing burden. The hybrid closed loop system proved most effective at keeping blood sugar in target range.
Research in mice found that early-life gut microbes shape insulin-producing cell development and reduce long-term changes in metabolism and diabetes risk. Exposure to a fungus called Candida dubliniensis during infancy may also promote lifelong metabolic health by supporting the growth of insulin-producing cells.